Comparing Ablative Modalities for Hepatocellular Carcinoma: Cautions in Interpreting Big Data
- PMID: 29945520
- PMCID: PMC6093787
- DOI: 10.1200/JCO.2018.78.5428
Comparing Ablative Modalities for Hepatocellular Carcinoma: Cautions in Interpreting Big Data
Conflict of interest statement
Disclosures provided by the authors are available with this article at jco.org.
Comment in
-
Reply to E.L. Pollom et al, N. Ohri et al, A. Fiorentino et al, D.R. Wahl et al, N. Kim et al, J. Boda-Heggemann et al, S. Rana et al, N. Sanuki et al, J.R. Olsen et al, G.L. Smith et al, and A. Shinde et al.J Clin Oncol. 2018 Aug 20;36(24):2567-2569. doi: 10.1200/JCO.2018.78.6418. Epub 2018 Jun 26. J Clin Oncol. 2018. PMID: 29945519 No abstract available.
Comment on
-
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database.J Clin Oncol. 2018 Feb 20;36(6):600-608. doi: 10.1200/JCO.2017.75.3228. Epub 2018 Jan 12. J Clin Oncol. 2018. PMID: 29328861
References
-
- Rajyaguru DJ, Borgert AJ, Smith AL, et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in non-surgically managed patients: Analysis of the National Cancer Database. J Clin Oncol. 2018;36:600–608. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical